Gavin MacBeath, CEO of TScan Therapeutics, takes us inside his journey from scientist to biotech leader and what it means to build and run a therapeutic development company at the cutting edge of immuno-oncology. He breaks down how TScan’s platform works to discover and match T-cell receptors (TCRs) with their antigens, and why TCR-T therapies may provide distinct benefits over CAR-T approaches, especially when tackling solid tumors. He also discusses which diseases are most likely to respond to TCR therapies and shares the latest updates on TScan’s clinical programs, from early-phase trials to an upcoming phase III study poised to shape the future of cancer treatment.

Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ 

Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA